Skip to main content

Advertisement

SpringerLink
Log in

Preoperative prognostic model for localized and locally advanced renal cell carcinoma: Michinoku Japan Urological Cancer Study Group

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

The Modified International Metastatic Renal Cell Carcinoma Dataset Consortium model (mIMDC) is a preoperative prognostic model for pT3cN0M0 renal cell carcinoma (RCC). This study aimed to validate the mIMDC and to construct a new model in a localized and locally advanced RCC (LLRCC).

Methods

A database was established (the Michinoku Japan Urological Cancer Study Group database) consisting of 79 patients who were clinically diagnosed with LLRCC (cT3b/c/4NanyM0) and underwent radical nephrectomy from December 2007 to May 2018. Using univariable and multivariable analyses, we retrospectively analyzed disease-free survival (DFS) and overall survival (OS) in this database, constructed a new prognostic model according to these results, and estimated the model fit using c-index on the new and mIMDC models.

Results

Independent poorer prognostic factors for both DFS and OS include the following: ≥ 1 Eastern Cooperative Oncology Group performance status, 2.0 mg/dL C-reactive protein, and > upper normal limit of white blood cell count. The median DFS in the favorable (no factor), intermediate (one factor), and poor-risk group (two or three factors) was 76.1, 14.3, and 4.0 months, respectively (P < 0.001). The 3-year OS in the favorable, intermediate, and poor-risk group were 92%, 44%, and 0%, respectively (P < 0.001). The c-indices of the new and mIMDC models were 0.67 and 0.60 for DFS (P = 0.060) and 0.74 and 0.63 for OS (P = 0.012), respectively.

Conclusion

The new preoperative prognostic model in LLRCC can be used in patient care and clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Dabestani S, Thorstenson A, Lindblad P et al (2016) Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J Urol 34(8):1081–1086. https://doi.org/10.1007/s00345-016-1773-y

    Article  PubMed  Google Scholar 

  2. Cosso F, Roviello G, Nesi G et al (2016) Adjuvant therapy for renal cell carcinoma: hype or hope?. Int J Mol Sci. https://doi.org/10.3390/ijms24044243

    Article  Google Scholar 

  3. Ravaud A, Motzer RJ, Pandha HS et al (2016) Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. https://doi.org/10.1056/NEJMoa1611406

    Article  PubMed  Google Scholar 

  4. Motzer RJ, Ravaud A, Patard JJ et al (2018) Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results. Eur Urol 73(1):62–68. https://doi.org/10.1016/j.eururo.2017.09.008

    Article  CAS  PubMed  Google Scholar 

  5. Haas NB, Manola J, Uzzo RG et al (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387(10032):2008–2016. https://doi.org/10.1016/s0140-6736(16)00559-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Motzer RJ, Haas NB, Donskov F et al (2017) Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol 35(35):3916–3923. https://doi.org/10.1200/jco.2017.73.5324

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Powles T, Tomczak P, Park SH et al (2022) Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23(9):1133–1144. https://doi.org/10.1016/s1470-2045(22)00487-9

    Article  CAS  PubMed  Google Scholar 

  8. Vogl UM, McDermott D, Powles T (2023) Adjuvant ipilimumab and nivolumab in renal cell carcinoma: more questions than answers. Lancet. https://doi.org/10.1016/s0140-6736(22)02631-9

    Article  PubMed  Google Scholar 

  9. Pal SK, Uzzo R, Karam JA et al (2022) Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet 400(10358):1103–1116. https://doi.org/10.1016/s0140-6736(22)01658-0

    Article  CAS  PubMed  Google Scholar 

  10. Haidar GM, Hicks TD, El-Sayed HF et al (2017) Treatment options and outcomes for caval thrombectomy and resection for renal cell carcinoma. J Vasc Surg Venous Lymphat Disord 5(3):430–436. https://doi.org/10.1016/j.jvsv.2016.12.011

    Article  PubMed  Google Scholar 

  11. Warren H, Fernando A, Thomas K et al (2019) Surgery for high-risk locally advanced (pT3c) renal tumours: oncological outcomes and prognostic significance of a modified International metastatic renal cell cancer database consortium (IMDC) score. BJU Int 124(3):462–468. https://doi.org/10.1111/bju.14755

    Article  PubMed  Google Scholar 

  12. Kattan MW, Reuter V, Motzer RJ et al (2001) A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166(1):63–67

    Article  CAS  PubMed  Google Scholar 

  13. Zisman A, Pantuck AJ, Dorey F et al (2001) Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19(6):1649–1657. https://doi.org/10.1200/jco.2001.19.6.1649

    Article  CAS  PubMed  Google Scholar 

  14. Frank I, Blute ML, Cheville JC et al (2002) An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 168(6):2395–2400. https://doi.org/10.1097/01.ju.0000035885.91935.d5

    Article  PubMed  Google Scholar 

  15. Leibovich BC, Blute ML, Cheville JC et al (2003) Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97(7):1663–1671. https://doi.org/10.1002/cncr.11234

    Article  PubMed  Google Scholar 

  16. Karakiewicz PI, Briganti A, Chun FK et al (2007) Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 25(11):1316–1322. https://doi.org/10.1200/jco.2006.06.1218

    Article  PubMed  Google Scholar 

  17. Cindolo L, de la Taille A, Messina G et al (2003) A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int 92(9):901–905. https://doi.org/10.1111/j.1464-410x.2003.04505.x

    Article  CAS  PubMed  Google Scholar 

  18. Leibovich BC, Lohse CM, Cheville JC et al (2018) Predicting oncologic outcomes in renal cell carcinoma after surgery. Eur Urol 73(5):772–780. https://doi.org/10.1016/j.eururo.2018.01.005

    Article  PubMed  Google Scholar 

  19. Mattila KE, Laajala TD, Tornberg SV et al (2021) A three-feature prediction model for metastasis-free survival after surgery of localized clear cell renal cell carcinoma. Sci Rep 11(1):8650. https://doi.org/10.1038/s41598-021-88177-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Dolan RD, Laird BJA, Klepstad P et al (2019) An exploratory study examining the relationship between performance status and systemic inflammation frameworks and cytokine profiles in patients with advanced cancer. Medicine 98(37):e17019. https://doi.org/10.1097/md.0000000000017019

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Ruan GT, Xie HL, Zhang HY et al (2022) Association of systemic inflammation and low performance status with reduced survival outcome in older adults with cancer. Clin Nutr 41(10):2284–2294. https://doi.org/10.1016/j.clnu.2022.08.025

    Article  CAS  PubMed  Google Scholar 

  22. Heng DY, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34):5794–5799. https://doi.org/10.1200/JCO.2008.21.4809

    Article  CAS  PubMed  Google Scholar 

  23. Patel SH, Derweesh IH, Saito K et al (2021) Preoperative elevation of C-reactive protein is a predictor for adverse oncologic survival outcomes for renal cell carcinoma: analysis from the international marker consortium renal cancer (INMARC). Clin Genitourin Cancer 19(4):e206–e215. https://doi.org/10.1016/j.clgc.2021.02.003

    Article  PubMed  Google Scholar 

  24. Hu H, Yao X, Xie X et al (2017) Prognostic value of preoperative NLR, dNLR, PLR and CRP in surgical renal cell carcinoma patients. World J Urol 35(2):261–270. https://doi.org/10.1007/s00345-016-1864-9

    Article  CAS  PubMed  Google Scholar 

  25. Naito S, Yamamoto N, Takayama T et al (2010) Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol 57(2):317–325. https://doi.org/10.1016/j.eururo.2008.12.026

    Article  CAS  PubMed  Google Scholar 

  26. Yasuda Y, Saito K, Yuasa T et al (2013) Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol 18(5):884–889. https://doi.org/10.1007/s10147-012-0454-0

    Article  CAS  PubMed  Google Scholar 

  27. Semeniuk-Wojtas A, Lubas A, Stec R et al (2018) Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and C-reactive Protein as new and simple prognostic factors in patients with metastatic renal cell cancer treated with tyrosine kinase inhibitors: a systemic review and meta-analysis. Clin Genitourin Cancer 16(3):e685–e693. https://doi.org/10.1016/j.clgc.2018.01.010

    Article  PubMed  Google Scholar 

  28. Santoni M, Buti S, Conti A et al (2015) Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Target Oncol 10(4):517–522. https://doi.org/10.1007/s11523-014-0356-3

    Article  PubMed  Google Scholar 

  29. Tachibana H, Nemoto Y, Ishihara H et al (2022) Predictive impact of early changes in serum C-Reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. Clin Genitourin Cancer 20(1):e81–e88. https://doi.org/10.1016/j.clgc.2021.10.005

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Yoichi Arai, Koji Mitsuzuka, and Takahiro Kojima for their invaluable support. We would also like to thank Enago (www.enago.jp) for the English language editing.

Author information

Authors and Affiliations

  1. Department of Urology, Faculty of Medicine, Yamagata University, Iida-Nishi 2-2-2, Yamagata, 990-9585, Japan

    Shigemitsu Horie, Sei Naito & Norihiko Tsuchiya

  2. Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 0368562, Japan

    Shingo Hatakeyama & Chikara Ohyama

  3. Department of Urology, University of Tsukuba Graduate School of Medicine, 1-1-1 Tennodai, Tsukuba, 305-8575, Japan

    Shuya Kandori & Hiroyuki Nishiyama

  4. Department of Urology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan

    Kazuyuki Numakura & Tomonori Habuchi

  5. Department of Urology, Iwate Medical University School of Medicine, Yahaba 2-1-1, Shiwa, Iwate, 028-3695, Japan

    Renpei Kato & Wataru Obara

  6. Department of Urology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan

    Tomoyuki Koguchi & Yoshiyuki Kojima

  7. Department of Urology, Miyagi Cancer Center, 47-1 Nodayama, Shiote, Medeshima, Natori, Miyagi, 981-1293, Japan

    Shingo Myoen & Hisanobu Adachi

  8. Department of Urology, Tohoku University School of Medicine, 1-1, Seiryo-Machi, Aoba-Ku, Sendai, Miyagi, 980-8574, Japan

    Yoshihide Kawasaki & Akihiro Ito

Authors
  1. Shigemitsu Horie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sei Naito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shingo Hatakeyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shuya Kandori
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazuyuki Numakura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Renpei Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tomoyuki Koguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shingo Myoen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yoshihide Kawasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Akihiro Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hisanobu Adachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yoshiyuki Kojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Wataru Obara
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Tomonori Habuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Hiroyuki Nishiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Chikara Ohyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Norihiko Tsuchiya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sei Naito.

Ethics declarations

Conflict of interest

Wataru Obara received honoraria from Ono, BMS, Merck, MSD, and Takeda, and resurch funding from Ono and BMS. Tomonori Habuci received honoraria from Janssen, Takeda, Asteras, Pfizer, and Novartis, and resurch funding Mochida pfarm. Norihiko Tsuchiya received honoraria from Pfizer, Merck, Eisai, Ono, Takeda, and BMS.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Horie, S., Naito, S., Hatakeyama, S. et al. Preoperative prognostic model for localized and locally advanced renal cell carcinoma: Michinoku Japan Urological Cancer Study Group. Int J Clin Oncol 28, 1538–1544 (2023). https://doi.org/10.1007/s10147-023-02401-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-023-02401-2

Keywords

Search

Navigation